

LETTER TO THE EDITOR

Open Access

Updating the diagnostic criteria of COVID-19 “suspected case” and “confirmed case” is necessary



Yun-Yun Wang¹, Ying-Hui Jin¹, Xue-Qun Ren², Yi-Rong Li^{3,4}, Xiao-Chun Zhang^{4,5}, Xian-Tao Zeng^{1,5*}, Xing-Huan Wang^{1,5*} and for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team

Abstract

On 6 February 2020, our team had published a rapid advice guideline for diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection, and this guideline provided our experience and make well reference for fighting against this pandemic worldwide. However, the coronavirus disease 2019 (COVID-19) is a new disease, our awareness and knowledge are gradually increasing based on the ongoing research findings and clinical practice experience; hence, the strategies of diagnosis and treatment are also continually updated. In this letter, we answered one comment on our guideline and provided the newest diagnostic criteria of “suspected case” and “confirmed case” according to the latest Diagnosis and Treatment Guidelines for COVID-19 (seventh version) that issued by the National Health Committee of the People’s Republic of China.

Keywords: COVID-19, SARS-CoV-2, 2019-nCoV, Guideline, Prevention, Diagnosis, Treatment, Novel coronavirus

Dear Editor,

In December 2019, the 2019 novel coronavirus (2019-nCoV) has caused an outbreak, which is now officially named as the coronavirus disease 2019 (COVID-19) and the virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 11 March 2020, WHO characterized COVID-19 as a pandemic [1]. In order to fight against the SARS-CoV-2 infection, our team has developed a rapid advice guideline and that has been published online in *Military Medical Research* on 06 February 2020 [2]. It has attracted a great attention

since published. Note however that COVID-19 is a new disease, our awareness and knowledge is gradually increasing based on the ongoing research findings and clinical practice experience [3–8]; hence, the strategies of diagnosis and treatment are also continually updated. For instance the *Diagnosis and Treatment Guidelines for COVID-19* issued by the National Health Committee of the People’s Republic of China (<http://www.nhc.gov.cn/>), among 16 January 2020 to 3 March 2020, has issued a total of seven editions with some contexts being substantively changed.

Now our guideline received a comment by Zhou et al. [9], they introduced a simple scoring proposal based on their clinical experience. Their work added new evidence for our guideline and also make valuable reference for this pandemic worldwide. We endorse their significant work and express our thanks. However, their work also needs update according to the latest *Diagnosis and*

This reply refers to the comment available online at <https://doi.org/10.1186/s40779-020-00246-8>.

* Correspondence: zengxiantao1128@163.com; wangxinghuan1965@163.com

This Letter to the Editor is to comment on the article published in *Military Medical Research*, 2020;7:4. <https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-0233-6>

¹Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Treatment Guidelines for COVID-19 (Trial seventh version) [10] and recently studies.

According to the seventh edition (3 March 2020), to confirm the suspected case needs to combine any one item of epidemiological history features with two items of clinical manifestations to make a comprehensive analysis, or needs to meet three items of clinical manifestations if without clear epidemiological history:

- Epidemiological history: (1) a history of travel or residence in Wuhan city and surrounding areas, or other communities where COVID-19 cases had been reported in the last 14 days before symptom onset; (2) a history of contact with SARS-CoV-2 infectious cases (with positive nucleic acid test); (3) a history of contacting with patients with fever or respiratory symptoms from Wuhan city and surrounding areas, or other communities where COVID-19 had been reported in the last 14 days before symptom onset; (4) a history of contacting with cluster of confirmed cases (≥ 2 cases with fever and/or respiratory symptoms occurred within 2 weeks in small areas, such as home, office, class of school, etc).
- Clinical manifestations: (1) fever and/ or respiratory symptoms; (2) with imaging features of COVID-19 infection; (3) total white blood cell counts showing normal, decreased, or reduced lymphocyte count in the early onset stage.

Diagnosing the confirmed case should base on suspected case with any one item of pathogenic or serological evidence as following: (1) real-time PCR test positive for SARS-CoV-2; (2) viral whole genome sequencing showing high homogeneity to the known novel coronaviruses; (3) positive for the specific IgM antibody and IgG antibody to SARS-CoV-2 in serum test; or a change of the SARS-CoV-2-specific IgG antibody from negative to positive, or titer rising ≥ 4 times in the recovery phase above that in the acute phase.

We can see that the real-time PCR test for nucleic acid in respiratory tract or blood samples was added to the second (18 January 2020) and third (22 January 2020) editions. The pathogenic detection of blood sample was added to the fourth (27 January 2020) and fifth (8 February 2020) editions; and then the serological evidence was added to the seventh edition. These modifications based on the researchers continued work that to search for an optimal nucleic acid detection kit for rapid diagnosis, as well as the samples from respiratory tract including blood sampling, which increased the availability of different specimens, and supported bringing the specific antibody positive result into the confirmed criteria [11–14].

Besides, there are more and more evidence that remind us to caution with the atypical symptomatic and

asymptomatic patients [13, 15–18]. Hence, the flow chart of Zhou et al. [9] should be updated, as they classified the person without clinical symptoms as “low risk”. The score system also needs to be verified in further clinical practice and studies.

To conclude, we hope more direct evidence coming up and call for readers to provide their comments. For the diagnosis of “suspected case” and “confirmed case”, we suggest to trace and obey the newest guidelines of their home countries. Our team will also timely update our guideline to offer help.

Abbreviations

2019-nCoV: 2019 novel coronavirus; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

Acknowledgements

Not applicable.

Authors' contributions

WXH and ZXT designed this letter; WYY and JYH collected and analysed data; ZXT, WYY, and JYH drafted this letter; RXQ, LYR, ZXC, and WXH reviewed this letter. All authors read and approved the final manuscript.

Funding

This study was supported, in part, by the National Key Research and Development Program of China (2020YFC0845500), the Special Project for Emergency Science and Technology of Hubei Province (2020FCA008), and the First Level Funding of the Second Medical Leading Talent Project of Hubei Province.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China. ²Institute of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, Henan, China. ³Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China. ⁴Leishenshan Hospital of Wuhan, Wuhan 430200, Hubei, China. ⁵Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.

Received: 19 March 2020 Accepted: 23 March 2020

Published online: 04 April 2020

References

1. World Health Organization. WHO characterizes COVID-19 as a pandemic - 11 March 2020. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>. Accessed 17 Mar 2020.
2. Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res*. 2020;7(1):4.
3. Tuite AR, Fisman DN. Reporting, epidemic growth, and reproduction numbers for the 2019 novel coronavirus (2019-nCoV) epidemic. *Ann Intern Med*. 2020. <https://doi.org/10.7326/m20-0358>.
4. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res*. 2020;7(1):11.

5. Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.25768>.
6. Jiang S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. *Nature*. 2020;579(7799):321.
7. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. *Travel Med Infect Dis*. 2020. <https://doi.org/10.1016/j.tmaid.2020.101623>.
8. Lippi G, Plebani M, Michael HB. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin Chim Acta*. 2020. <https://doi.org/10.1016/j.cca.2020.03.022>.
9. Zhou TT, Wei FX. Primary stratification and identification of suspected Corona Virus Disease 2019 (COVID-19) from clinical perspective by a simple scoring proposal. *Mil Med Res*. 2020. <https://doi.org/10.1186/s40779-020-00246-8>.
10. General Office of National Health Committee, Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of a programme for the diagnosis and treatment of COVID-19 (Trial Version 7). 2020. <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml>. Accessed 17 Mar 2020.
11. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. 2020. <https://doi.org/10.1001/jama.2020.3786>.
12. Pfeifferle S, Reucher S, Norz D, Lutgehetmann M. Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. *Euro Surveill*. 2020. <https://doi.org/10.2807/1560-7917.Es.2020.25.9.2000152>.
13. Tang A, Tong ZD, Wang HL, Dai YX, Li KF, Liu JN, et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child. *China Emerg Infect Dis*. 2020. <https://doi.org/10.3201/eid2606.200301>.
14. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. *J Clin Microbiol*. 2020. <https://doi.org/10.1128/jcm.00310-20>.
15. Wang WG, Hu H, Song L, Gong XM, Qu YJ, Lv YZ. Image of pulmonary and diagnosis of atypical novel coronavirus (2019-nCoV) infected pneumonia: case series of 14 patients. *New Med*. 2020;30(1):7-9. <https://doi.org/10.12173/j.jissn.1004-5511.2020.01.04>.
16. Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis*. 2020. <https://doi.org/10.1016/j.ijid.2020.03.020>.
17. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. *J Microbiol Immunol Infect*. 2020. <https://doi.org/10.1016/j.jmii.2020.02.012>.
18. Bwire GM, Paulo LS. Coronavirus disease-2019: is fever an adequate screening for the returning travelers? *Trop Med Health*. 2020;48:14. <https://doi.org/10.1186/s41182-020-00201-2>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

